The sale is small and routine, likely for tax purposes. Monitor for any larger insider sales or changes in officer shareholding patterns in upcoming Form 4 filings.
VIR drugs
VIR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $11.22entry
- T+1 · 13d ago +4.90%α +3.25% · $11.77
- T+5 · 7d ago +17.20%α +17.79% · $13.15
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vanina de Verneuil, an officer of Vir Biotechnology, filed a Form 144 notice of intent to sell 2,407 shares of common stock, valued at approximately $26,718 based on the filing date price. The shares were acquired through restricted stock vesting on November 1, 2026. The proposed sale is small relative to the company's $2.0B market cap and appears to be a routine transaction to cover tax withholding or diversify holdings.
Key Facts
- Officer Vanina de Verneuil filed Form 144 to sell 2,407 shares of Vir Biotechnology common stock.
- Estimated aggregate value of the proposed sale is $26,717.70.
- Shares were acquired on November 1, 2026 via restricted stock vesting from the issuer.
- The sale is planned for execution on or after November 3, 2026 on Nasdaq.
- The proposed sale represents a negligible fraction of the company's $2.0B market cap.
Financial Impact
Proposed sale of 2,407 shares worth approximately $26,718, immaterial relative to $2.0B market cap.
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur.
- No context on the officer's total beneficial ownership was provided, so proportionality to holdings cannot be fully assessed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-007669 |
| Document: 0001959173-26-007669-index.html | 0001959173-26-007669 |
| Document: 0001959173-26-007669.txt | 0001959173-26-007669 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Viewing Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers